Hemophilia a Trials in Milan, Italy
Conditions / Hemophilia a / Milan, Italy
Hemophilia a has been the subject of sustained clinical investigation across multiple research sites.
48 total trials for this combination
Showing top 10 of 48 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02615691 | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A | COMPLETED | PHASE3 |
| NCT04644575 | Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00623727 | BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A | TERMINATED | PHASE2 |
| NCT05145127 | Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors | RECRUITING | — |
| NCT02078427 | ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) | COMPLETED | — |
| NCT00157157 | Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients | COMPLETED | PHASE3 |
| NCT01454739 | Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A | COMPLETED | PHASE3 |
| NCT05145127 | Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors | RECRUITING | — |
| NCT02234323 | An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A | COMPLETED | PHASE3 |
| NCT02585960 | BAX 855 PK-guided Dosing | COMPLETED | PHASE3 |